202 related articles for article (PubMed ID: 37318031)
21. Tumor-Infiltrating Lymphocytes, Tumor Mutational Burden, and Genetic Alterations in Microsatellite Unstable, Microsatellite Stable, or Mutant
Keshinro A; Vanderbilt C; Kim JK; Firat C; Chen CT; Yaeger R; Ganesh K; Segal NH; Gonen M; Shia J; Stadler Z; Weiser MR
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250404
[TBL] [Abstract][Full Text] [Related]
22. Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring
Wen L; Chen Z; Ji X; Fong WP; Shao Q; Ren C; Cai Y; Li B; Yuan Y; Wang D; Li Y
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793867
[TBL] [Abstract][Full Text] [Related]
23. Immune Checkpoint Inhibitors in pMMR/MSS Colorectal Cancer.
El Hajj J; Reddy S; Verma N; Huang EH; Kazmi SM
J Gastrointest Cancer; 2023 Dec; 54(4):1017-1030. PubMed ID: 37009977
[TBL] [Abstract][Full Text] [Related]
24. Microsatellite Stable Colorectal Cancer With an Immunogenic Phenotype: Challenges in Diagnosis and Treatment.
Saller J; Qin D; Felder S; Coppola D
Clin Colorectal Cancer; 2020 Jun; 19(2):123-131. PubMed ID: 32171644
[TBL] [Abstract][Full Text] [Related]
25. Current Landscape and Potential Challenges of Immune Checkpoint Inhibitors in Microsatellite Stable Metastatic Colorectal Carcinoma.
San-Román-Gil M; Torres-Jiménez J; Pozas J; Esteban-Villarrubia J; Albarrán-Fernández V; Álvarez-Ballesteros P; Chamorro-Pérez J; Rosero-Rodríguez D; Orejana-Martín I; Martínez-Delfrade Í; Reguera-Puertas P; Fuentes-Mateos R; Ferreiro-Monteagudo R
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765821
[TBL] [Abstract][Full Text] [Related]
26. Predictive molecular markers for the treatment with immune checkpoint inhibitors in colorectal cancer.
Du F; Liu Y
J Clin Lab Anal; 2022 Jan; 36(1):e24141. PubMed ID: 34817097
[TBL] [Abstract][Full Text] [Related]
27. Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer.
Lin A; Zhang J; Luo P
Front Immunol; 2020; 11():2039. PubMed ID: 32903444
[TBL] [Abstract][Full Text] [Related]
28. Targeting MSS colorectal cancer with immunotherapy: are we turning the corner?
Wang C; Fakih M
Expert Opin Biol Ther; 2021 Oct; 21(10):1347-1357. PubMed ID: 34030532
[TBL] [Abstract][Full Text] [Related]
29. Utility of Tumor Mutational Burden as a Biomarker for Response to Immune Checkpoint Inhibition in the VA Population.
Scobie MR; Zhou KI; Ahmed S; Kelley MJ
JCO Precis Oncol; 2023 Sep; 7():e2300176. PubMed ID: 38039430
[TBL] [Abstract][Full Text] [Related]
30. Pembrolizumab for the treatment of colorectal cancer.
Coupez D; Hulo P; Touchefeu Y; Bossard C; Bennouna J
Expert Opin Biol Ther; 2020 Mar; 20(3):219-226. PubMed ID: 31952453
[No Abstract] [Full Text] [Related]
31. An update on the use of immunotherapy in patients with colorectal cancer.
Nguyen M; Tipping Smith S; Lam M; Liow E; Davies A; Prenen H; Segelov E
Expert Rev Gastroenterol Hepatol; 2021 Mar; 15(3):291-304. PubMed ID: 33138649
[No Abstract] [Full Text] [Related]
32. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors.
Cristescu R; Aurora-Garg D; Albright A; Xu L; Liu XQ; Loboda A; Lang L; Jin F; Rubin EH; Snyder A; Lunceford J
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101941
[TBL] [Abstract][Full Text] [Related]
33. Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer.
Akin Telli T; Bregni G; Vanhooren M; Saude Conde R; Hendlisz A; Sclafani F
Cancer Treat Rev; 2022 Nov; 110():102460. PubMed ID: 36058142
[TBL] [Abstract][Full Text] [Related]
34. Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study.
Antoniotti C; Korn WM; Marmorino F; Rossini D; Lonardi S; Masi G; Randon G; Conca V; Boccaccino A; Tomasello G; Passardi A; Swensen J; Ugolini C; Oberley M; Tamburini E; Casagrande M; Domenyuk V; Fontanini G; Giordano M; Abraham J; Spetzler D; Falcone A; Lenz HJ; Cremolini C
Eur J Cancer; 2021 Sep; 155():73-84. PubMed ID: 34365081
[TBL] [Abstract][Full Text] [Related]
35. A comprehensive analysis of POLE/POLD1 genomic alterations in colorectal cancer.
Mosalem O; Coston TW; Imperial R; Mauer E; Thompson C; Yilma B; Bekaii-Saab TS; Stoppler MC; Starr JS
Oncologist; 2024 May; ():. PubMed ID: 38776551
[TBL] [Abstract][Full Text] [Related]
36. Somatic POLE exonuclease domain mutations elicit enhanced intratumoral immune responses in stage II colorectal cancer.
Mo S; Ma X; Li Y; Zhang L; Hou T; Han-Zhang H; Qian J; Cai S; Huang D; Peng J
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32859741
[TBL] [Abstract][Full Text] [Related]
37. Multiomic molecular characterization of the response to combination immunotherapy in MSS/pMMR metastatic colorectal cancer.
Takei S; Tanaka Y; Lin YT; Koyama S; Fukuoka S; Hara H; Nakamura Y; Kuboki Y; Kotani D; Kojima T; Bando H; Mishima S; Ueno T; Kojima S; Wakabayashi M; Sakamoto N; Kojima M; Kuwata T; Yoshino T; Nishikawa H; Mano H; Endo I; Shitara K; Kawazoe A
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38336371
[TBL] [Abstract][Full Text] [Related]
38. Interplay between Tumor Mutational Burden and Mutational Profile and Its Effect on Overall Survival: A Pilot Study of Metastatic Patients Treated with Immune Checkpoint Inhibitors.
Xavier CB; Lopes CDH; Awni BM; Campos EF; Alves JPB; Camargo AA; Guardia GDA; Galante PAF; Jardim DL
Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358851
[TBL] [Abstract][Full Text] [Related]
39. Presence of Tim3
Klapholz M; Drage MG; Srivastava A; Anderson AC
J Pathol; 2022 Jun; 257(2):186-197. PubMed ID: 35119692
[TBL] [Abstract][Full Text] [Related]
40. How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation.
Wang Q; Shen X; Chen G; Du J
Int J Cancer; 2023 Aug; 153(4):709-722. PubMed ID: 36752642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
